Hirokazu Iso

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Topics

Advanced Non Small Cell Lung Cancer

Liver Metastases

Top Venues

OncoTargets and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Hirokazu Iso, Akihiko Miyanaga, Naohiro Kadoma, Kaoruko Shinbu, Takehiro Tozuka, Akari Murata, Shunichi Nishima, Yozo Sato, Shinji Nakamichi, Masaru Matsumoto, Rintaro Noro, Yasuhiro Terasaki, Kaoru Kubota, Masahiro Seike
Remarkable Clinical Response of ALK -Rearranged/ TP53 -Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report. OncoTargets and therapy 16 (2023)
Hirokazu Iso, Akihiko Miyanaga, Naohiro Kadoma, Kaoruko Shinbu, Takehiro Tozuka, Akari Murata, Shunichi Nishima, Yozo Sato, Shinji Nakamichi, Masaru Matsumoto, Rintaro Noro, Yasuhiro Terasaki, Kaoru Kubota, Masahiro Seike
Remarkable Clinical Response of ALK -Rearranged/ TP53 -Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report. OncoTargets and therapy 16 (2023)
Hirokazu Iso, Akihiko Miyanaga, Naohiro Kadoma, Kaoruko Shinbu, Takehiro Tozuka, Akari Murata, Shunichi Nishima, Yozo Sato, Shinji Nakamichi, Masaru Matsumoto, Rintaro Noro, Yasuhiro Terasaki, Kaoru Kubota, Masahiro Seike
Remarkable Clinical Response of ALK -Rearranged/ TP53 -Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report. OncoTargets and therapy 16 (2023)
Hirokazu Iso, Akihiko Miyanaga, Naohiro Kadoma, Kaoruko Shinbu, Takehiro Tozuka, Akari Murata, Shunichi Nishima, Yozo Sato, Shinji Nakamichi, Masaru Matsumoto, Rintaro Noro, Yasuhiro Terasaki, Kaoru Kubota, Masahiro Seike
Remarkable Clinical Response of ALK -Rearranged/ TP53 -Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report. OncoTargets and therapy 16 (2023)